Andrea Lobo, PhD,  science writer—

Children and adolescents with cystic fibrosis (CF) treated with Kaftrio, marketed as Trikafta in the U.S., experienced increases in the fat-soluble vitamins D and A for up to one year, according to a study from Spain. Treatment reduced the proportion of participants with vitamin D and vitamin A…

Treatment with Trikafta (elexacaftor/tezacaftor/ivacaftor) contributed to a reduction in pulmonary exacerbations requiring hospitalization between 2018 and 2022 among children and young adults with cystic fibrosis (CF). That’s according to a recent study in the U.S. that also demonstrated that the proportion of hospitalized CF patients from minority groups,…

Researchers at the University of California, Los Angeles (UCLA) are developing a gene-editing therapy — designed to be delivered as a one-time inhalable treatment — that aims to correct the underlying mutations that cause cystic fibrosis (CF). The team is using tiny fat-based particles to deliver the gene-editing machinery…

Poor sleep quality is linked to a higher risk of malnutrition in adolescents with cystic fibrosis (CF), suggesting that sleep disturbances may contribute to added nutritional challenges in these patients, a study in Turkey shows. The effects weren’t influenced by patients’ body mass index (BMI) percentile, a measure of…

Discoveries into the process underlying protein organization on cell membranes could ultimately lead to new ways to treat cystic fibrosis (CF), according to a study from Canada that shed light on some of the mechanisms underlying the disease. The study found that proteins linked to CF organize themselves into clusters…

Volatile organic compounds (VOCs) found in breath may be used as biomarkers of lung function and treatment response in children with cystic fibrosis (CF) and mild lung disease, a pilot study in France showed. The study compared breath composition before and up to six months after children initiated Kaftrio…

The U.K. Medicines and Healthcare Products Regulatory Agency approved Alyftrek (vanzacaftor, tezacaftor, and deutivacaftor) as a cystic fibrosis (CF) treatment for patients ages 6 and older. The triple-combination CFTR modulator, developed by Vertex Pharmaceuticals, is indicated for patients who have at least one copy of a responsive…

Among children with cystic fibrosis (CF), starting the approved oral therapy Orkambi (ivacaftor/lumacaftor) led to favorable changes in lung function and structure after one year, a real-world study shows. Improvements were seen in markers of small airway function and structural changes, including the lung clearance index (LCI), indicating…

In adults with cystic fibrosis (CF), six of months treatment with Kaftrio (elexacaftor/tezacaftor/ivacaftor) led to lower levels of biomarkers of inflammation, but higher blood levels of fat-like molecules considered to be cardiovascular risk factors, according to a recent study in Italy. While highly effective, the triple-combination therapy — available…

Oransi has donated air purifiers to help people with cystic fibrosis (CF) affected by smoke-filled air from the wildfires that flared up last month in Southern California, Claire’s Place Foundation said. The foundation’s financial assistance program provides CF patients and their families with one-time funds for air purifiers,…